Therapeutic trial of Réaktin.3TR against COVID-19

Project summary In order to verify as soon as possible, the effectiveness of Réaktin.3T Laboratoire.3T la Vie, on those tested positive and patients with Covid-19, a competence partnership has been set up between the Fablab Laboratoire.3Tla Vie on the one hand, also called A, the pharmacology department of the FMSB / UY1 and LANACOME on the other hand, also called B. In accordance with their respective skills: A will supply the product to be tested in accordance with the requirements described. B Check the quality of the lots. Goals Réaktin.3TR, the beneficial effects of which are manifested from the 2nd day of treatment in bedridden HIV-AIDS patients in particular, [Marketing Authorization No. 1209 / D / MINSANTE / SG / DPS / SDAN / SCOA of June 2, 2016], could allow to lead a preventive and curative fight against the Covid-19 pandemic. Its administration should allow: In the population: reduce the number of infected people Among infected people: reduce the number of sick people Among the sick: to reduce the death rate, increasing cures. To do this: Réaktin.3TR will be administered to non-contaminated people at risk to boost their defense. Réaktin.3TR will be administered very early in those who test positive to attenuate or even abort the clinical picture. Réaktin.3TR will be administered alone or with the usual drugs in people with Covid-19.